Thermo Fisher Scientific INC Form 4 insider transactions

Jennifer M. Johnson, a Director at Thermo Fisher Scientific Inc., acquired 76.54 phantom stock units as part of the company's deferred compensation plan, increasing her beneficial ownership to 474.05 units.

Thomas B. Shropshire Jr., SVP and General Counsel of Thermo Fisher Scientific Inc., reported the acquisition of 5,417 shares of common stock and 15,530 stock options.

Thermo Fisher Scientific's CEO, Marc Casper, reports acquisition of performance-based restricted stock units and updates to his beneficial ownership.

Director Nelson Chai reports changes in beneficial ownership of Thermo Fisher Scientific common stock, including acquisition and disposal of shares on May 21, 2025.

Director Ruby R. Chandy reports acquisition and disposal of Thermo Fisher Scientific common stock.

Director C. Martin Harris of Thermo Fisher Scientific reports acquiring and disposing of common stock on May 21, 2025.

Director R. Alexandra Keith reports acquisition and disposal of Thermo Fisher Scientific common stock on May 21, 2025.

Director James C. Mullen reports acquisition and disposal of Thermo Fisher Scientific common stock.

Director Debora L. Spar reports acquisition and disposal of Thermo Fisher Scientific Inc. common stock.

Director Karen S. Lynch reports acquisition and disposal of Thermo Fisher Scientific Inc. common stock.

Jennifer M. Johnson, a director at Thermo Fisher Scientific, reported the acquisition and disposal of common stock on May 21, 2025.

Director Tyler Jacks reported acquiring and disposing of Thermo Fisher Scientific Inc. common stock on May 21, 2025.

Director Dion J. Weisler reports changes in beneficial ownership of Thermo Fisher Scientific stock, including acquisitions and disposals.

Director Scott Sperling reports acquisition and disposal of Thermo Fisher Scientific Inc. common stock on May 21, 2025.

Executive Vice President of Thermo Fisher Scientific, Gianluca Pettiti, reports the sale of 400 shares of common stock at a price of $411.11 per share.

Executive Vice President of Thermo Fisher Scientific, Gianluca Pettiti, reports the sale of 300 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Director Dion J. Weisler reports acquisition of phantom stock units in Thermo Fisher Scientific Inc. through a deferred compensation plan.

Director Scott M. Sperling reports acquisition of phantom stock units in Thermo Fisher Scientific through a deferred compensation plan.

Director Karen S. Lynch reports acquisition of phantom stock units in Thermo Fisher Scientific's Deferred Compensation Plan for Directors.

Director R. Alexandra Keith acquired phantom stock units in Thermo Fisher Scientific through the company's Deferred Compensation Plan for Directors.

Director Jennifer M. Johnson acquired phantom stock units in Thermo Fisher Scientific Inc. through the company's Deferred Compensation Plan for Directors.

Michael Boxer, SVP and General Counsel of Thermo Fisher Scientific, reported the sale of 3,775.48 shares of common stock on March 10, 2025.

Thermo Fisher Scientific's CEO, Marc Casper, exercised stock options and sold shares of common stock on March 4th and 5th, 2025, under a pre-arranged trading plan.

Frederick M. Lowery, Executive Vice President of Thermo Fisher Scientific, reports the disposal of shares due to an adjustment in a performance-based restricted stock unit award.

Stephen Williamson, CFO of Thermo Fisher Scientific, reports an adjustment in his holdings of performance-based restricted stock units due to the company's relative total shareholder return.

Executive Vice President Michael D. Shafer reports stock transactions, including the sale of shares and adjustments to performance-based restricted stock units, according to a Form 4 filing.

Executive Vice President Gianluca Pettiti of Thermo Fisher Scientific reports disposition of shares to cover tax obligations related to vesting of restricted stock units.

Michel Lagarde, Executive Vice President & COO of Thermo Fisher Scientific, reports an adjustment in the number of performance-based restricted stock units received due to the company's relative total shareholder return.

Joseph R. Holmes, VP & Chief Accounting Officer of Thermo Fisher Scientific, reports an adjustment in the number of shares received from a performance-based restricted stock unit award due to the company's relative total shareholder return.

Thermo Fisher Scientific's CEO, Marc Casper, reports an adjustment in his holdings of common stock due to the performance-based vesting of restricted stock units.